Recent Food and Drug Administration (FDA) approval of diagnostic and therapeutic
radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to …

Despite implementing hundreds of strategies, cancer drug development suffers from a 95%
failure rate over 30 years, with only 30% of approved cancer drugs extending patient …

Positron emission tomography (PET) is a powerful tool for imaging biological processes in
the central nervous system (CNS). Designing PET radiotracers capable of crossing the …

Our research group recently identified a rearrangement product of pirenzepine as starting
point for a comprehensive rational drug design approach towards orthosteric muscarinic …

Ligand-based virtual screening (LBVS) has rarely been tested as a method for discovering
new structural scaffolds for PET radioligand development. This study used LBVS to discover …

Chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with
repetitive mild traumatic brain injury, is characterized neuropathologically by abnormal …

The prediction of central nervous system (CNS) active pharmaceuticals and
radiopharmaceuticals has experienced a boost by the introduction of computational …

Positron emission tomography imaging of misfolded proteins with high‐affinity and selective
radioligands has played a vital role in expanding our knowledge of neurodegenerative …

Imaging biomarkers have changed the way we study Alzheimer's disease and related
dementias, develop new therapeutics to treat the disease, and stratify patient populations in …

Abstract The International Atomic Energy Agency (IAEA) held the 3rd International
Symposium on Trends in Radiopharmaceuticals,(ISTR-2023) at IAEA Headquarters in …